Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

l StudiesThe two fidaxomicin Phase 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a total of 1,164 adult subjects.  Subjects with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the only FDA approved product for the treatment of CDI. These studies were designed to evaluate safety and compare the response to treatment in subjects during and after a 10-day course of therapy. The primary endpoint was non-inferiority compared to Vancocin in clinical cure (defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator).  If cured, subjects were monitored for a subsequent four-week period to evaluate recurrence, which was a secondary endpoint.  Global cure, also a secondary endpoint, was defined as patients who were cured and did not have a recurrence during this subsequent four-week period. In both of these studies, fidaxomicin achieved its primary endpoint of non-inferiority compared to Vancocin.  Fidaxomicin was also statistically superior to Vancocin in global cure rate and in reducing recurrences of CDI.

About Clostridium difficile InfectionCDI has become a significant medical problem in hospitals, long-term care facilities, and in the community.  It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produces toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, and thus allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially res
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 ... announced the addition of the "Global PDT ... offering.        (Logo: ... Report 2014 is a professional and in-depth study ... , ,The report provides a basic overview of ...
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, ... of positive interim results from a poster presented ... open label randomised phase III trial of the ... in patients receiving cisplatin (Cis) monotherapy for standard ... the American Society of Clinical Oncology (ASCO) 2015 ...
(Date:6/1/2015)... Sistemic Ltd. and RoosterBio Inc. ... commercial collaboration agreement and signed a memorandum of ... and work together towards advancing the field of ... Sistemic will collaborate on utilizing microRNA (miRNA)-based cell ... and relevant characterization panels for hMSC products and ...
(Date:6/1/2015)... -- Berg, a biopharmaceutical company committed to uncovering health solutions ... its trials using its cancer drug BPM 31510 on ... negative breast cancer, at the 51 st Annual ... May 29 – June 2 in Chicago ... of the first cancer drugs guided in development by ...
Breaking Biology Technology:Global PDT Machine Industry Report 2014 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 2Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 3Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3
... , Introduction , ... almost all color , vision and most of the ... known as the macula , lutea, or yellow spot, ... and zeaxanthin. , These compounds are both, ...
... Polyphosphoinositides and their metabolites are, ... responses to a number of hormones and growth, ... that phosphorylates PI at the 3 position of, ... metabolism and potential intracellular signals., ...
... , Agencourt offers sequencing services designed specifically for ... cDNA sequencing and finishing. Agencourt , has many features ... with rapid project turnaround including: Comprehensive genomic , ... High throughput, GLP-compliant facility , ...
Cached Biology Technology:Purification of the Components of Human Macular Carotenoid-Binding Complex, , Rev A 2Purification of the Components of Human Macular Carotenoid-Binding Complex, , Rev A 3Purification of Phosphoinositide 3-Kinase With UNO Columns 2cDNA Sequencing & Finishing 2
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... considered sexy, but it may prove a permanent turn on for ... BMC Genomics could help explain why former smokers are still more ... A Canadian team led by Wan L Lam and Stephen ... of 24 current and former smokers, as well as from non-smokers ...
... Government priorities can drive local waste partnerships towards the ... wider sustainable waste management objectives, a study funded by ... levels of waste and disposing of it in environmentally ... in other areas of public service delivery, partnership working ...
... may soon be cleaner thanks to an innovative approach ... and funded by the U.S. Environmental Protection Agency (EPA). ... and planners select the most efficient and site specific ... controlling the amount of pollutants that enter the receiving ...
Cached Biology News:Smoking turns on genes -- permanently 2Central targets may hinder wider waste management objectives 2Central targets may hinder wider waste management objectives 3Innovative civil engineering application promises cleaner waters 2Innovative civil engineering application promises cleaner waters 3
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... identification through targeting resequencing. This ... assay validation/optimization, high throughput PCR setup ... samples and sequence alignment and analysis.,Agencourts ... and highly accurate identification of SNP ...
... JMP 6 delivers enhanced statistics and ... and quality improvement managers. As an ... JMP 6 simplifies statistics for novice ... needed by experts. It offers a ...
Biology Products: